LianBio(LIANY)

Description: LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

---

Keywords: Biopharmaceutical Solid Tumors Autoimmune Disease Inflammatory Diseases Heart Failure Ulcerative Colitis Diarrhea Crohn's Disease Radiotherapy Colitis Abdominal Pain Cholangiocarcinoma Head And Neck Squamous Cell Carcinoma Chronic Rhinosinusitis Blepharitis Hypertrophic Cardiomyopathy Malignant Tumor Meibomian Gland Demodex Meibomian Gland Disease Obstructive And Non Obstructive Hypertrophic Cardiomyopathy

---

Home Page: www.lianbio.com

103 Carnegie Center Drive
Princeton, NJ 08540
United States
Phone: 609 486 2308

---

Officers

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)